BlueGenes provides an AI‑powered pharmacogenetics platform that delivers rapid, point‑of‑care genetic test results integrated directly into electronic health records and pharmacy benefit manager systems.
Funding
Funding not disclosed
Founders
Product
Problem
Adverse drug reactions (ADRs) remain a leading cause of hospitalizations and mortality because clinicians often lack patient-specific genetic information when prescribing medications. Traditional pharmacogenetic testing is slow, disconnected from prescribing workflows, and does not provide actionable guidance at the point of care.
Solution
BlueGenes offers an AI‑powered pharmacogenetics platform that delivers real‑time genetic test results integrated directly into electronic health records, pharmacy benefit manager systems, and other clinical workflows. A simple cheek swab collects buccal DNA, which is analyzed for key CYP enzymes and drug‑response genes. Within minutes, the platform generates clear prescribing recommendations that flag potential ADRs and suggest alternative therapies. The AI engine continuously updates guidance as new drug‑gene evidence emerges, ensuring clinicians receive the most current, evidence‑based advice at the moment of decision. By embedding these insights into existing prescribing processes, BlueGenes enables providers and payers to prevent harmful prescriptions and reduce unnecessary medication use at scale.
Target Audience
Primary customers are healthcare providers, pharmacy benefit managers, and health plans seeking to incorporate pharmacogenetic insights into prescribing and formulary decisions.
Features
- Rapid buccal swab collection kit with a 7‑10 day turnaround for full PGx report
- AI-driven decision support that provides immediate, drug‑specific dosing or alternative recommendations
- Seamless integration via APIs with EMR, PBM, and pharmacy dispensing systems for point‑of‑care alerts
- Secure, FISMA‑compliant data handling with automatic DNA destruction after analysis
- Comprehensive reporting portal offering PDF reports, drug interaction visualizations, and optional pharmacist consults
- Expanded gene panel including GLP‑1 pathway variants for metabolic and obesity treatment personalization